- $2.61bn
- $2.81bn
- $421.88m
- 96
- 20
- 86
- 75
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 264 | 303 | 346 | 372 | 422 |
Cost of Revenue | |||||
Gross Profit | 206 | 240 | 294 | 313 | 354 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 227 | 269 | 313 | 324 | 352 |
Operating Profit | 36.6 | 33.8 | 33.3 | 47.4 | 70.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 3.19 | 4.86 | 11.6 | 30.4 | 44.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.51 | -7.16 | 0.113 | 16.7 | 23.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.51 | -7.16 | 0.113 | 16.7 | 23.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.51 | -7.16 | 0.113 | 16.7 | 23.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.016 | -0.045 | 0.001 | 0.106 | 0.131 |
Dividends per Share |